IMMUCELL CORP /DE/ 8-K

What Happened
ImmuCell Corporation announced on April 8, 2026 (via an 8-K and press release) that preliminary, unaudited product sales for the quarter ended March 31, 2026 increased 28.4% versus Q1 2025. The company reported this in an Item 2.02 filing covering results of operations and financial condition.

Key Details

• Reported change: product sales up 28.4% in Q1 2026 compared with Q1 2025.
• Period covered: quarter ended March 31, 2026; announcement date: April 8, 2026.
• Data status: preliminary and unaudited (company explicitly notes results are preliminary).
• Filing note: company provided the announcement via a press release attached to the Form 8-K.

Why It Matters
A near-30% year-over-year increase in product sales for the quarter is a notable sign of accelerating revenue activity for a small-cap company like ImmuCell. Because the figures are preliminary and unaudited, investors should wait for formal quarterly financial statements and any follow-up guidance before changing valuations or positions. The 8-K signals positive quarterly momentum but does not replace the detail and assurance of audited results.